Cargando…

CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5‐LSD1‐NF‐κB oncogenic signaling

RATIONALE: CD13 is a new marker for liver cancer stem cells (CSCs) that contributes to sorafenib resistance in hepatocellular carcinoma (HCC). However, the underlying mechanism of CD13 in HCC sorafenib resistance remains enigmatic. METHODS: The expression of CD13 in HCC cell lines and tissues was as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Bo, Xu, Yang, Li, Yuan‐Cheng, Huang, Jun‐Feng, Cheng, Jian‐Wen, Guo, Wei, Yin, Yue, Gao, Yang, Wang, Peng‐Xiang, Wu, Sui‐Yi, Zhou, Jian, Fan, Jia, Yang, Xin‐Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708822/ https://www.ncbi.nlm.nih.gov/pubmed/33377659 http://dx.doi.org/10.1002/ctm2.233

Ejemplares similares

Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth
por: Dudgeon, Crissy, et al.
Publicado: (2012)

Epigenetic regulation of LSD1 during mammary carcinogenesis
por: Wu, Yadi, et al.
Publicado: (2014)

Phosphorylation of NF-κBp65 drives inflammation-mediated hepatocellular carcinogenesis and is a novel therapeutic target
por: Xu, Xuan, et al.
Publicado: (2021)

Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer
por: Gajendran, Chandru, et al.
Publicado: (2023)

Aerobic glycolysis enhances HBx-initiated hepatocellular carcinogenesis via NF-κBp65/HK2 signalling
por: Chen, Lingjun, et al.
Publicado: (2022)

Natural chalcones as dual inhibitors of HDACs and NF-κB
por: ORLIKOVA, B., et al.
Publicado: (2012)

Oncogenic mechanisms of HOXB13 missense mutations in prostate carcinogenesis
por: Cardoso, Marta, et al.
Publicado: (2016)

HDAC7 Activates IKK/NF-κB Signaling to Regulate Astrocyte-Mediated Inflammation
por: Ye, Jinwang, et al.
Publicado: (2022)

PLEKHG5 is stabilized by HDAC2-related deacetylation and confers sorafenib resistance in hepatocellular carcinoma
por: Sha, Yu, et al.
Publicado: (2023)

The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats
por: Li, Nan, et al.
Publicado: (2017)

A combination of sorafenib and radiotherapy reduces NF-κB activity and growth of hepatocellular carcinoma in an orthotopic mouse model
por: Chuang, Hui-Yen, et al.
Publicado: (2021)

Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
por: Lu, Haofeng, et al.
Publicado: (2022)

B1, a novel HDAC inhibitor, induces apoptosis through the regulation of STAT3 and NF-κB
por: Cheng, Meng-Hsuan, et al.
Publicado: (2017)

HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice
por: Afaloniati, Hara, et al.
Publicado: (2020)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

Oncogenes and radiation carcinogenesis.
por: Garte, S J, et al.
Publicado: (1991)

NKILA represses nasopharyngeal carcinoma carcinogenesis and metastasis by NF-κB pathway inhibition
por: Zhang, Wei, et al.
Publicado: (2019)

Oncogenic Akt-FOXO3 loop favors tumor-promoting modes and enhances oxidative damage-associated hepatocellular carcinogenesis
por: Lu, Miao, et al.
Publicado: (2019)

ABHD12 contributes to tumorigenesis and sorafenib resistance by preventing ferroptosis in hepatocellular carcinoma
por: Cai, Mengxing, et al.
Publicado: (2023)

HDAC-mediated Deacetylation of NF-κB is Critical for Schwann cell Myelination
por: Chen, Ying, et al.
Publicado: (2011)

Sumoylation of HDAC2 promotes NF-κB-dependent gene expression
por: Wagner, Tobias, et al.
Publicado: (2015)

Involvement of NF-κB/IL-6 Pathway in the Processing of Colorectal Carcinogenesis in Colitis Mice
por: Yang, Hang, et al.
Publicado: (2014)

Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells
por: Haydn, Tinka, et al.
Publicado: (2017)

Mechanism of Crosstalk between the LSD1 Demethylase and HDAC1 Deacetylase in the CoREST Complex
por: Song, Yun, et al.
Publicado: (2020)

Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines
por: Zhang, Zhi, et al.
Publicado: (2020)

The role of oncogenes in chemical carcinogenesis.
por: Stowers, S J, et al.
Publicado: (1987)

Pharmacological inhibition of LSD1 suppresses growth of hepatocellular carcinoma by inducing GADD45B
por: Sang, Na, et al.
Publicado: (2023)

Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib
por: Zheng, Ning, et al.
Publicado: (2019)

The Homeotic Protein SIX3 Suppresses Carcinogenesis and Metastasis through Recruiting the LSD1/NuRD(MTA3) Complex
por: Zheng, Yu, et al.
Publicado: (2018)

Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis
por: Zhang, Jinglin, et al.
Publicado: (2019)

Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells
por: Bulut, Ipek, et al.
Publicado: (2022)

Epidermal p65/NF-κB signalling is essential for skin carcinogenesis
por: Kim, Chun, et al.
Publicado: (2014)

Attribution of NF-κB Activity to CHUK/IKKα-Involved Carcinogenesis
por: Li, Xin, et al.
Publicado: (2021)

Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition
por: Davis, McKale R., et al.
Publicado: (2016)

Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model
por: Chen, John Chun-Hao, et al.
Publicado: (2016)

KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition
por: Hu, Bo, et al.
Publicado: (2019)

CD147 reinforces [Ca(2+)](i) oscillations and promotes oncogenic progression in hepatocellular carcinoma
por: Tang, Juan, et al.
Publicado: (2015)

Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus
por: Zhang, Yong-Fa, et al.
Publicado: (2016)

Effects of Sensitized Sorafenib with a Paeoniflorin and Geniposide Mixture on Liver Cancer via the NF-κB-HIF-2α-SerpinB3 Pathway
por: Li, Jun-Fei, et al.
Publicado: (2022)

The HDAC Inhibitor Quisinostat (JNJ-26481585) Supresses Hepatocellular Carcinoma alone and Synergistically in Combination with Sorafenib by G0/G1 phase arrest and Apoptosis induction
por: He, Bin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0uqnrn7o6l0tkr6gr2072n753e